|
gptkbp:instanceOf
|
immunosuppressant
topical medication
|
|
gptkbp:administeredBy
|
topical
|
|
gptkbp:approvedBy
|
2001
|
|
gptkbp:ATCCode
|
D11AH02
|
|
gptkbp:brand
|
gptkb:Elidel
|
|
gptkbp:CASNumber
|
137071-32-0
|
|
gptkbp:contraindication
|
active viral infection
hypersensitivity to pimecrolimus
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:drugClass
|
immunotherapy
|
|
gptkbp:eliminationHalfLife
|
30-40 hours
|
|
gptkbp:EMA_approved
|
yes
|
|
gptkbp:FDAApproved
|
yes
|
|
gptkbp:form
|
gptkb:butter
|
|
gptkbp:hasMolecularFormula
|
C43H68N2O11
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pimecrolimus
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits T-cell activation
inhibits release of inflammatory cytokines
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
810.02 g/mol
|
|
gptkbp:notRecommendedFor
|
children under 2 years
|
|
gptkbp:patent
|
gptkb:Novartis
|
|
gptkbp:powers
|
1%
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
topical
|
|
gptkbp:sideEffect
|
pruritus
burning sensation
erythema
irritation
|
|
gptkbp:usedFor
|
gptkb:eczema
gptkb:atopic_dermatitis
|
|
gptkbp:bfsParent
|
gptkb:Elidel
gptkb:Fujimycin
|
|
gptkbp:bfsLayer
|
7
|